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Ten patients with advanced congestive heart failure were 
treated with an arginine vasopressin V I antagonist dur•
ing hemodynamic monitoring to determine the contri•
bution of vasopressin to vasoconstriction in this disorder. 
The vasopressin antagonist caused a decrease in systemic 
vascular resistance in the three patients whose plasma 
vasopressin was greater than 4.0 pg/ml (average for the 
group was 2.4 ± 0.6). Plasma vasopressin concentration 
correlated with the percent decrease of systemic vascular 
resistance (r = 0.70, p < 0.025), serum sodium (r = 
0.72, p < 0.02) and serum creatinine (r = 0.85, p < 
0.005). To compare the relative roles of vasopressin, the 
renin-angiotensin system and the sympathetic nervous 
system, these patients also received captopril and phen•
tolamine. Captopril decreased systemic vascular resist•
ance by 20% (p < 0.05), mostly in patients with high 
plasma renin activity. Levels of plasma renin activity 
In patients with congestive heart failure, elevated vascular 
resistance may result from sympathetic nervous system stim•
ulation and from increased activity of the renin-angiotensin 
system (1). Several investigators have speculated that neu•
rohypophyseal secretion of vasopressin may also be a con•
tributing factor, because its concentration is often increased 
both in animal models of low output cardiac failure and in 
some patients with congestive heart failure (2-9), especially 
in the presence of hyponatremia (6,7). However, it has not 
yet been established whether these plasma levels contribute 
to vasoconstriction. 
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ranged between 1 and 46 ng/ml per h (average 14.7 ± 
5.7) and correlated with serum sodium (r = 0.77, P < 
0.025), serum creatinine (r = 0.73, P < 0.025) and right 
atrial pressure (r = 0.67, p < 0.05). Phentolamine de•
creased systemic vascular resistance in all patients (av•
erage 34%, p < 0.01), but the decrease did not correlate 
with the pretreatment norepinephrine concentration. 
Norepinephrine levels were elevated in all patients 
(694 ± 110 pg/ml) and correlated with baseline stroke 
volume index (r = 0.75, p < 0.025) and plasma renin 
activity (r = 0.67, P < 0.05). 
It is concluded that vasopressin and the renin-angio•
tensin system each contribute to systemic vasoconstric•
tion in some patients with heart failure, whereas the 
sympathetic nervous system consistently contributes to 
vasoconstriction in these patients. 
(J Am Coli CardioI1986;7:758-65) 
Accordingly, the primary purpose of this investigation 
was to establish whether vasopressin contributes to the in•
creased systemic vascular resistance that often occurs in 
these patients. Vasopressin concentrations were determined 
by radioimmunoassay. and the pressor response was studied 
by the use of a vasopressin V 1 antagonist. In addition to the 
vasopressin antagonist, patients also received the alpha-ad•
renergic antagonist phentolamine and the angiotensin-con•
verting enzyme inhibitor captopril to assess the relative con•
tributions of each of the three pressor systems to systemic 
vascular resistance in congestive heart failure. 
Methods 
Patients. Ten men with chronic congestive heart failure, 
aged 50 to 78 years (60.4 ± 9.5, mean ± SD), participated 
in this study. Causes of heart failure were primary cardio•
myopathy in seven patients, coronary artery disease in one 
patient and severe left ventricular dysfunction secondary to 
valvular heart disease in two patients, both of whom had 
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previously undergone valve replacement. Eight patients were 
in New York Heart Association functional class III and two 
patients were in class IV. Duration of symptoms ranged 
from 2 months to 5 years and averaged 23.5 ± 22 months. 
The radionuclide left ventricular ejection fraction averaged 
24.1 ± 10.1%. 
All studies were conducted in the postabsorptive state 
without premedication. Vasodilator medications were dis•
continued at least 48 hours before the study, and digitalis 
and diuretic drugs were withheld for at least 24 hours pre•
ceding the experiment. Clinically indicated antiarrhythmic 
drugs were continued throughout the protocol. Dietary so•
dium was restricted to 2 g/day. The protocol was approved 
by the Institutional Review Board for Human Studies at 
Boston University Medical Center, and each subject gave 
written informed consent. 
Hemodynamic measurements. Right heart catheteriza•
tion was performed in each patient with a Swan-Ganz cath•
eter (Edwards Laboratories) and a cannula was placed in 
the radial artery. Pressures were measured by using a Hew•
lett-Packard model I280B strain gauge transducer and re•
corded on a direct-writing Hewlett-Packard mUltigraph. Mean 
pressures were obtained by electronic integration. Zero ref•
erence was chosen to be at the right atrium, estimated to 
be 5 cm vertically beneath the sternal angle of Louis. Heart 
rate was determined from a simultaneous electrocardio•
graphic signal. Cardiac output was determined in eight pa•
tients by thermodilution using an Edwards model 9520A 
bedside computer averaging three successive measurements 
differing by less than 10%. In two patients, cardiac output 
was determined by the Fick technique using a Beckman 
Metabolic cart (Beckman Instruments, Inc.) comprising a 
volume transducer and a Beckman OM-II oxygen analyzer 
to determine minute volume oxygen consumption. In those 
patients, blood was collected for arterial and mixed venous 
oxygen content and analyzed on a Lex-02-Con oxygen ana•
lyzer (Lexington Instruments). Measurements were obtained 
for systolic, diastolic and mean systemic arterial and pul•
monary artery pressures, pulmonary capillary wedge pres•
sure and right atrial pressure. The left ventricular filling 
pressure was defined as the pulmonary capillary wedge pres•
sure, or as the pulmonary artery diastolic pressure if this 
had been previously found to be consistent with the pul•
monary capillary wedge pressure. Hemodynamic indexes 
and systemic and pulmonary arteriolar resistance were cal•
culated from pressure and cardiac output values according 
to standard formulas (10). 
Protocol. All patients were studied in the recumbent 
position. Systemic hemodynamic data were collected until 
three successive determinations at 15 minute intervals dem•
onstrated homeostasis. Mixed venous blood was collected 
for determinations of plasma arginine vasopressin concen•
tration, plasma norepinephrine concentration and plasma 
renin activity. In addition, blood was collected for deter-
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minations of plasma osmolality, blood urea nitrogen, cre•
atinine, sodium and potassium. 
To study the pressor effect of physiologic levels of vaso•
pressin, a competitive antagonist of the vasoconstrictor ac•
tion of vasopressin at the vascular VI receptors was utilized. 
This compound, [1-(J3-mercapto-J3, J3-cyclopentameth•
ylenepropionic acid) 2(0-methyl) tyrosine] arginine vaso•
pressin, was administered intravenously over a 5 minute 
period at a dose of 0.5 mg. This dosage had previously 
been shown (11) to inhibit 80% of the blood pressure re•
sponse after administration of exogenous vasopressin at a 
dose of 20 mU/kg body weight. Hemodynamic measure•
ments were repeated at 5, 10, 15, 30 and 60 minutes after 
administration of the vasopressin antagonist. Blood was col•
lected 60 minutes after drug administration for hormonal 
measurements as well as for plasma osmolality, serum cre•
atinine, blood urea nitrogen, sodium and potassium. 
The sympathetic nervous system was inhibited by admin•
istration of the alpha-adrenergic antagonist phentolamine 
as a 5.0 mg intravenous bolus given over 2 minutes, fol•
lowed by a 1 mg/min infusion. Hemodynamic measure•
ments were obtained at 5, 10 and 15 minutes, and blood 
was collected for hormonal assays 15 minutes after the initial 
bolus. The renin-angiotensin system was inhibited by cap•
topril, administered orally at a dose of25 mg. Hemodynamic 
measurements were repeated at 15,30,60 and 120 minutes, 
and blood was collected for hormonal assays and determi•
nation of creatinine, sodium and potassium levels 60 min•
utes after captopril administration. 
Each subject received all three drugs sequentially. The 
initial drug was randomly chosen to be either the vasopressin 
antagonist or phentolamine; the final drug was captopril. 
Baseline hemodynamic values were reestablished and blood 
was collected for determination of chemistry values and 
hormonal assays before the administration of each drug. 
The interval between administration of the vasopressin an•
tagonist and phentolamine was 3 hours. Captopril was given 
2 to 4 hours thereafter. or the following morning. 
Hormonal assays. Plasma vasopressin levels were de•
termined by radioimmunoassay (12). Because the antibody 
cross-reacts with the vasopressin antagonist, the concentra•
tion of endogenous vasopressin could not be determined 
after administration of the antagonist. Plasma norepineph•
rine concentration was measured by radioenzymatic assay 
(13), and plasma renin activity was determined by radioim•
munoassay (14). Plasma osmolality was measured by the 
freezing point method. 
Statistical analysis. Values are expressed as mean ± 
SEM. Data before and after drug intervention were com•
pared by analysis of variance for repeated measures with 
trend analysis. Paired values before and after treatment were 
evaluated by the Wilcoxon-Mann-Whitney rank-sum statis•
tic for nonGaussian distribution. Linear regression analysis 
was used to correlate the pretreatment hormonal measure-
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Figure 1. Baseline plasma arginine vasopressin (A VP), plasma 
renin activity (PRA) and plasma norepinephrine (NE) in each patient. 
ments with selected hemodynamic variables. Statistical sig•
nificance was accepted at tne 95% confidence level (p < 
0.05). 
Re~ults 
Plasma vasopressin concentration and the hemody•
namic response to the vasopressin antagonist. Before 
administration of the vasopressin antagonist, vasopressin 
levels ranged from 0.7 to 6.2 pg/ml (average 2.4 ± 0.6) 
(Fig. 1). In our laboratory, normal vasopressin values for 
fully hydrated subjects are l.l ± 0.2 pg/ml with an in•
traassay and interassay coefficient of variation of less than 
6 and 10%, respectively. Only 3 of the 10 patients had 
vasopressin levels exceeding normal values. 
Systemic vascular resistance decreased and cardiac in•
dex increased after administration of the vasopressin an•
tagonist in each of the three patients whose vasopressin 
levels were above normal (Table 1). In these patients, max-
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Figure 2. Correlation of baseline arginine vasopressin (A VP) with 
percent change in systemic vascular resistance (SVR) after admin•
istration of the vasopressin antagonist. 
imal effects pccurred 15 to 30 minutes after drug admin•
istration. In five of the patients with normal vasopressin 
levels, systemic vascular resistance increased after drug in•
fusion. For the 10 patients, therefpre, baseline plasma vaso•
pressin levels correlated inversely with the percent change 
in systemic vascular resistance (r = 0.70, P < 0.025) and 
approached a significant correlation with the percent change 
in cardiac index (r = 0.62, P = 0.06) (Fig. 2). For the 
group, however, the vasopressin antagonist caused no sig•
nificant chaf!ge in systolic, diastolic or mean blood pressure, 
systolic, diastolic or mean pulmonary artery pressure, left 
ventricular filling pressure, right atrial pressure or heart rate 
(Table 2. Fig. 3). Furthermore, there were no significant 
changes in cardiac index or stroke volume index. Neither 
systemic vascular resistance nor p~lmqnary arteriolar re•
sistance was significantly altered by vasopressin blockade. 
The vasopressin antagonist did not alter the serum so•
dium (136 ± 1 mEq/liter), potassium (3.8 ± 0.1 mEql 
liter), creatinine (1.2 ± 0.1 mg/dl) or blood urea nitrogen 
Table 1. Effect of the Vasopressin Antagonist on Systemic Hemodynamics 
BP CI SVR LVFP RAP HR 
Vasopressin (mm Hg) (liters/min per m2) (dynes's.cm - 5) (mm Hg) (mm Hg) (beats/min) 
Level 
Case (pg/ml) Pre post Pre Post Pre Post Pre Post Pre Post Pre Post 
1 1.3 72 73 3.1 2.9 922 1,003 20 20 4 4 85 81 
2 0.7 100 105 1.0 1.0 3,953 4,500 28 30 16 15 78 90 
3 0.8 82 75 1.7 1.5 1,578 1,725 17 13 11 6 84 66 
4 4.2 100 95 1.9 2.2 1,682 1,418 32 33 18 17 84 84 
5 4.5 83 80 1.5 1.8 1,522 1,168 34 33 24 26 90 92 
6 I.5 90 99 2.7 3.2 1,409 1,348 21 23 9 8 85 88 
7 1.7 78 75 2.5 2.6 1,260 1,208 14 21 4 78 76 
8 1.5 85 92 2.0 1.8 1,825 2,179 26 32 12 13 101 110 
9 6.2 85 85 1.9 2.1 \,806 1,647 24 26 15 15 118 120 
10 1.8 82 90 2.2 1.9 1,562 1,946 23 18 0 0 84 85 
Mean 2.4 86 87 2.0 2.2 1,752 1,814 24 25 11 10 89 89 
± SEM 0.6 3 4 0.2 0.2 259 320 2 2 2 2 4 5 
BP =' mean blood pressure; CI =' cardiac index; HR =' heart rate; L VFP =' left ventricular filling pressure; Post =' after treatment; Pre = before 
treatment; RAP = right atrial pressure; SVR =' systemic vascular resistance. 
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Table 2. Hemodynamic Response to the Plasma Arginine Vasopressin (AVP) Antagonist, Captopril anq Phentolamine in 10 Patients 
BP PAP LVFP RAP HR CI SVI SVR PAR 
(mmHg) (mm Hg) (mmHg) (mmHg) (beats/min) (liters/mm per m') (mllm') ( dynes's'cm -5) (dynes.s'cm - 5) 
Baseline 
Mean 85.7 36.2 239 11.3 88.7 20 235 1,752 291 
SEM 2.8 2 I 2.0 23 3.li 0.2 25 259 43 
A VP antagonist 
Mean 86.9 37.4 24.7 10.3 892 2.2 25.6 1.814 260 
SEM 3.5 2 I 22 :2 5 5.0 0.2 26 320 41 
Baseline 
Mean 88.0 37.7 27.7 109 89.9 2.3 256 1,758 233 
SEM 28 2.8 2.7 2.4 41 0.2 2.5 373 56 
Captopril 
Mean 78.7* 32.3* 21.3t 10.3 85.2* 25 30.0* 1,203* 195 
SEM 44 3.3 2.7 22 43 0.1 1.7 82 22 
Baseline 
Mean 849 37.9 25.5 11.9 883 2.2 26.2 1,538 262 
SEM 3.3 2.8 2.2 2.5 37 0.2 2.6 192 44 
Phentolamine 
Mean 77.7t 30.3* 18.5* 78* 95 1* 34t 35.lt 984t 198 
SEM 3.1 3.5 32 2.4 2.6 0.4 3.6 134 34 
Statistical significance IS mdicated as *p < 0.05 and tp < 001 PAP = mean pulmonary artery pressure: PAR = pulmonary artenolar resIstance; 
SVI = stroke volume mdex: SVR = systemic vascular resIstance: other abbreviations as m Table I. 
(21 ± 3 mg/dl) levels. The baseline plasma vasopressin 
concentration correlated inversely with the pretreatment serum 
sodium concentration (r = -0.72, p < 0.02) and directly 
with the baseline serum creatinine concentration (r = 0.85, 
P < 0.005). There was no correlation between the baseline 
Figure 3. The maximal hemodynamic response to the vasopressin 
antagonist (AVP), captopril and phentolamine. Hemodynamic 
variables are indicateQ.Jis percent change (mean ± SEM) from 
pretreatment values. BP = mean blood pressure: CI = cardiac 
index; HR = heart rate; L VFP = left ventricular filling pressure; 
RAP = right atrial pressure; SVI = stroke volume index: SVR = 
systemic vascular resistance. 
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vasopressin concentration and the baseline plasma osmo•
lality. Plasma osmolality ranged from 277 to 294 mOsml 
liter (average 285 ± 2). Plasma osmolality in th~ three 
patients with an elevated vasopressin concentration was 277 , 
281 and 293 mOsmlliter, respectively. 
Pretreatment vasopressin concentration did not correlate 
with baseline plasma norepinephrine concentration or plasma 
renin activity. The vasopressin antagonist did not affect 
plasma norepinephrine concentration (764 ± 154 to 661 ± 
127 pg/ml, p = NS) but caused a modest, yet significant, 
decrease in plasma renin activity (14.1 ± 5.6 to 12.1 ± 
4.8 ng/ml per h, p < 0.05). 
Plasma renin activity and the hemodynamic response 
to captopril. Normal values of plasma renin activity in our 
laboratory range between 2 and 5 ng/ml per h, with intraas•
say and jnterassay coefficients of variation of less than 1 
and 2%, respectively. In the patients with congestive heart 
failure, before captopril treatment, plasma renin activity 
ranged from I to 46 ng/ml perh (average 14.7 ± 5.7) (Fig. 
1). In five patients, plasma renin activity was less than 3 
ng/ml per h, and in four patients, levels were greater than 
20 ng/ml per h. 
The maximal hemodynamic response to captopril oc•
curred 60 minutes after drug administration (Table 2, Fig. 
3). Captopril decreased mean blood pressure by 11 % (p < 
0.025), mean pulmonary artery pressure by 14% (p < 0.025), 
left ventricular filling pressure by 23% (p < 0.01) and heart 
rate by 5% (p < 0.05). Stroke volume index increased by 
36% (p < 0.05), but there was no significant change in 
cardiac index. This can be attributed, in part, to the decrease 
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in heart rate. Systemic vascular resistance declined in 7 of 
the iO patients. and the average decline for the whole group 
was 20% (p < 0.05). In the five patients whose baseline 
plasma renin activity was not elevated, captopril decreased 
systemic vascular resistance by 6%. Of the five patients 
with elevated baseline plasma renin activity, systemic vas•
cular resistance declined by 49%. This is due to a large 
decrease in systemic vascular resistance in four of these 
patients. 
Plasma renin activity increased from 14.7 ± 5.7 to 
38.6 ± 14.3 ng/ml per h (p < 0.025) after captopril admin•
istration. No change occurred in plasma norepinephrine 
concentration after converting enzyme inhibition (954 ± 
292 to 920 ± 3 iO pg/ml, p = NS). Captopril did not 
significantly change serum sodium (136 ± 1 mEq/liter), 
potassium (3.6 ± 0.1 mEq/liter), creatinine (1.1 ± 0.1 
mg/dl) or blood urea nitrogen (19 ± 3 mg/dl) levels. Pre•
treatment plasma renin activity correlated inversely with the 
baseline serum sodium concentration (r = - 0.77, P < 
0.025) and directly with the pretreatment serum creatinine 
(r = 0.73, P < 0.025). blood urea nitrogen (r = 0.72, P 
< 0.025), right atrial pressure (r = 0.67, P < 0.05) and 
plasma norepinephrine concentration (r = 0.72, P < 0.025). 
Plasma norepinephrine concentration and the hemo•
dynamic response to phentolamine. In our laboratory, the 
normal range for plasma norepinephrine is ISO to 300 pg/ 
ml. The intraassay and interassay coefficients of variation 
are less than 10%. In each patient with congestive heart 
failure, plasma norepinephrine concentration was increased 
above normal values, ranging from 305 to 1,302 pg/ml 
(average 694 ± 110) (Fig. I). 
The maximal hemodynamic response to phentolamine oc•
curred after 15 minutes of drug infusion (Table 2, Fig. 3). 
Phentolamine significantly decreased mean blood pressure 
by 8% (p < 0.01), mean pulmonary artery pressure by 20% 
(p < 0.05), left ventricular filling pressure by 27% (p < 
0.05) and right atrial pressure by 34% (p < 0.05). After 
phentolamine administration, heart rate increased by 8% 
(p < 0.05), cardiac index increased by 52% (p < 0.01) and 
stroke volume index increased by 39% (p < 0.01). Phen•
tolamine decreased systemic vascular resistance by 34% (p 
< 0.01) but did not significantly alter pulmonary arteriolar 
resistance. During the phentolamine infusion, plasma nor•
epinephrine increased from 694 ± 110 to 1,113 ± 251 pg/ 
ml (p < 0.01). There was a small but significant increase 
in plasma renin activity from 11.4 ± 4.1 to 14.5 ± 5.1 
ng/ml per h (p < 0.05). 
The pretreatment plasma norepinephrine concentration 
correlated inversely with the baseline stroke volume index 
(r = - 0.75, P < 0.025) and directly with heart rate (r = 
0.85, P < 0.01). Pretreatment plasma norepinephrine cor•
related directly with pretreatment plasma renin activity 
(r = 0.67, P < 0.05). There was no correlation between 
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the baseline norepinephrine level and the change III any 
hemodynamic variable. 
Discussion 
This is the first evidence that vasopressin contributes to 
systemic vascular resistance in some patients with conges•
tive heart failure. Each of the patients whose plasma vaso•
pressin levels exceeded normal values had a systemic vaso•
dilatory response to the vasopressin antagonist. 
Vasopressin levels in congestive heart failure. 
Elevated plasma levels of vasopressin have been previously 
reported in animal models of low output heart failure 
(2-4). In patients with congestive heart failure, plasma 
vasopressin concentration is often, but not always, increased 
(5-9). Yamane (5) reported that plasma vasopressin con•
centration was increased in approximately 33% of patients 
with heart failure. Szatalowicz et al. (7) found that 30 of 
37 patients with heart failure and hyponatremia had de•
tectable vasopressin levels, but only 6 had levels greater 
than 4.0 pg/ml. In 6 of 20 patients studied by Riegger et 
al. (6), vasopressin levels were considered disproportion•
ately high for the corresponding plasma osmolality. These 
observations are consistent with our study in which plasma 
vasopressin concentration was elevated in only 3 of 10 pa•
tients. 
The vasopressin concentration that had been observed in 
some patients with congestive heart failure was sufficient 
to enhance renal tubular reabsorption of water (15-18). It 
was not known, however, whether these concentrations of 
vasopressin also caused vasoconstriction. Experimentally, 
vasoconstriction does occur when physiologic doses of vaso•
pressin are applied to the femoral artery (19). Animal studies 
(20,21) have shown that vasopressin, when endogenously 
secreted during dehydration, hemorrhage or hyperosmolal•
ity, has a vasopressor effect. Vasopressin has a more pro•
nounced pressor action in animals subjected to baroreceptor 
denervation, sympathectomy and nephrectomy (22,23). On 
the basis of these experimental observations, it is reasonable 
to postulate that endogenously secreted vasopressin 
can increase vascular resistance in human beings. 
Vasopressin antagonist. Few studies have examined the 
vasopressor effect of endogenous vasopressin in humans. 
Recently, the availability of a specific pharmacologic probe, 
that is, an antagonist of vasopressin at the vascular V I re•
ceptors, offered the possibility of a more accurate assess•
ment of its pressor action. When administered to normally 
hydrated, healthy subjects, this vasopressin antagonist did 
not alter blood pressure (24). However, it did decrease blood 
pressure in sodium-loaded patients with end-stage renal dis•
ease whose plasma vasopressin concentration was increased 
above normal values (11). In our study, the vasopressin 
antagonist decreased systemic vascular resistance in the three 
patients with heart failure whose vasopressin levels were 
JACC Vol 7. No.4 
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elevated. However, in five patients with normal levels of 
vasopressin, systemic vascular resistance increased after drug 
administration. Thus, the drug may have agonistic prop•
erties in patients with heart failure with low to normal vaso•
pressin levels. 
Variables associated with elevated vasopressin lev•
els. The reason why only 30% of the patients had elevated 
levels of vasopressin is not clear. Vasopressin concentration 
correlated inversely with serum sodium concentration and 
directly with blood urea nitrogen and serum creatinine con•
centration. Although renal function was grossly normal in 
our patients, creatinine clearance was not measured. It is 
therefore conceivable that renal metabolism of vasopressin 
was diminished in those patients with elevated levels. The 
inverse relation to serum sodium may reflect the renal tu•
bular effects of vasopressin. Of the three patients in whom 
vasopressin was increased, plasma osmolality was elevated 
in one and low in two. Sodium contributes to plasma os•
molality. Sodium and osmolality were closely associated in 
most but not all of the patients. Thus, even though vaso•
pressin levels correlated with sodium concentration, a sig•
nificant relation with plasma osmolality was not found. A 
larger number of patients may be required for sufficient 
statistical power to demonstrate a correlation between vaso•
pressin and osmolality. 
The relation of vasopressin secretion to the renin-angio•
tensin system and sympathetic nervous system is complex. 
Angiotensin II has been variably reported to increase or 
have no effect on vasopressin levels, and norepinephrine 
has been reported to decrease vasopressin levels (25-28). 
We were unable to demonstrate any relation between plasma 
renin activity or plasma norepinephrine concentration and 
plasma vasopressin levels. 
Each of the three patients with elevated vasopressin lev•
els had a high right atrial pressure. In the studies reported 
by Yamane (5), plasma vasopressin concentration tended to 
be higher in patients with increased right ventricular end•
diastolic pressure. In the anesthetized dog, cardiopulmonary 
receptors tonically inhibit the release of vasopressin (29). 
In humans, however, the interaction of the cardiopulmonary 
receptors and neurohypophyseal secretion of vasopressin is 
not well defined. Acutely altering right atrial pressure in 
normal volunteers by volume expansion, lower body pos•
itive pressure or lower body negative pressure does not 
increase plasma vasopressin concentration, although vaso•
pressin levels do rise after prolonged postural tilt (30-32). 
Francis, Goldsmith and colleagues (33,34) were unable to 
detect any significant changes in plasma vasopressin con•
centration in patients with heart failure after tilt, or after 
decreasing cardiac filling pressures with nitroprusside. 
Renin-angiotensin system in congestive heart fail•
ure. The second objective of this investigation was to de•
termine the relative contributions of vasopressin, the renin•
angiotensin system and the sympathetic nervous system to 
CREAGER ET AL 
VASOPRESSIN IN CONGESTIVE HEART FAILURE 
763 
systemic vascular resistance in the same patients. The con•
tribution of the renin-angiotensin system to systemic vas•
cular resistance in patients with congestive heart failure has 
been confirmed by the work of many investigators (35-38). 
Elevated plasma renin activity. however, is not a uniform 
finding in all patients. and pretreatment plasma renin activity 
varied widely in our patient popUlation. In five patients, 
plasma renin activity was within normal limits and in four, 
it was greater than 20 ng/ml per h. The decrease in systemic 
vascular resistance was greatest in those patients with the 
highest plasma renin activity. Thus, the renin-angiotensin 
system was a major contributor to systemic vascular re•
sistance in many but not all of the patients with congestive 
heart failure. 
Pretreatment plasma renin activity correlated directly 
with pretreatment plasma norepinephrine concentration and 
also with right atrial pressure. suggesting that baroreceptors 
may contribute indirectly to activation of the renin-angio•
tensin system. This is consistent with findings in normal 
subjects in whom the renin response to postural tilt is in•
hibited by adrenergic blockade (32). In addition, plasma 
renin activity correlated inversely with serum sodium con•
centration. The relation between plasma renin activity and 
sodium has been reported by other investigators (39-41). 
Sympathetic nervous system in congestive heart fail•
ure. The most consistent finding in these patients was an 
elevated plasma norepinephrine concentration. In each pa•
tient, plasma norepinephrine exceeded normal values. The 
pretreatment concentration of norepinephrine correlated in•
versely with stroke volume index, suggesting an association 
between poor cardiac function and increased sympathetic 
nervous system activity. Similar observations have been 
reported previously (42-44). 
During alpha-adrenergic blockade, systemic vasodila•
tion occurred in every patient. The decrease in systemic 
vascular resistance was greater in magnitude than that after 
administration of either captopril or the vasopressin antag•
onist. The baseline norepinephrine concentration, however, 
did not predict the hemodynamic response to phentolamine. 
Several facts may explain the failure to demonstrate a re•
lation between plasma norepinephrine concentration and the 
vascular response to phentolamine. The plasma level of 
norepinephrine gives an estimate but not an absolute mea•
sure of sympathetic nervous system activity (45). Thus, the 
levels determined in this study may only approximate the 
contribution of the sympathetic nervous system to vasocon•
striction. Because phentolamine inhibits both alphat- and 
alpha2-adrenergic receptors, it may potentiate the presyn•
aptic release of norepinephrine. Indeed. plasma norepi•
nephrine concentration increased during the phentolamine 
infusion. Thus, a chronotropic and possibly inotropic re•
sponse to phentolamine contributed to the improvement in 
cardiac function and may have indirectly altered vascular 
resistance. In addition to its alpha-adrenergic blocking ca-
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pability, phentolamine may dilate vessels directly. Further•
more, plasma renin activity and, presumably, angiotensin 
II. increased during the phentolamine infusion and may have 
affected the vascular response. 
Significance of short- versus long-term treatment. 
This study examined the short-term physiologic effects of 
three neurohormonal antagonists. The initial hemodynamic 
response to these drugs, however, may not predict the long•
term clinical response. For example, long-term captopril 
therapy may result in clinical improvement in patients who 
did not have a systemic vasodilatory response to the first 
dose (46). Conversely, long-term treatment with alpha-ad•
renergic antagonists may not be beneficial despite initial 
hemodynamic efficacy (47). Thus, the short-term response 
to the vasopressin antagonist may differ from the effects of 
long-term vasopressin blockade. 
Conclusions. We found that plasma vasopressin was in•
creased in 30% of patients with congestive heart failure. As 
determined by the vasodilator response to the vasopressin 
antagonist in these patients, endogenously secreted vaso•
pressin can contribute to systemic vascular resistance. Plasma 
renin activity was increased in 50% of patients. As judged 
by the vasodilator response to captopril in these individuals, 
the renin-angiotensin system is often a determinant of sys•
temic vascular resistance. Only the sympathetic nervous 
system uniformly contributed to systemic vasoconstriction 
in these patients. Plasma norepinephrine was increased in 
every patient and each patient had a substantial vasodilator 
response to phentolamine. Additional studies are required 
to determine which specific factors activate each neural or 
hormonal mediator of vasoconstriction and to examine the 
complex relations that exist between these vasoactive systems. 
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